1. Forde PM, Kelly RJ, Brahmer JR. New strategies in lung cancer: translating
immunotherapy into clinical practice. Clin Cancer Res. 2014;20(5):1067–
73. https://doi.org/10.1158/1078-0432.CCR-13-0731.
2. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, da Ho
JC, da Chu T, Zaatar A, OsorioSanchez JA, Vu VV, Au JS, Inoue A, Lee SM,
Gebski V, Yang JC. Impact of EGFR inhibitor in non-small cell lung cancer
on progression-free and overall survival: a meta-analysis. J Natl Cancer
Inst. 2013;105(9):595–605. https://doi.org/10.1093/jnci/djt072.
3. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A,
Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby
MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, KEYNOTE-024
Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://
doi.org/10.1056/NEJMoa1606774.
4. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny
Costa E, Park K, Alexandru A, Lupinacci L, de la Mora JE, Sakai H, Albert I,
Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer
JR, O’Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan
RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced
non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31. https://
doi.org/10.1056/NEJMoa1910231.
5. Driehuis E, Kretzschmar K, Clevers H. Establishment of patientderived cancer organoids for drug-screening applications. Nat Protoc.
2020;15(10):3380–409. https://doi.org/10.1038/s41596-020-0379-4.
6. Huo KG, D’Arcangelo E, Tsao MS. Patient-derived cell line, xenograft
and organoid models in lung cancer therapy. Transl Lung Cancer Res.
2020;9(5):2214–32. https://doi.org/10.21037/tlcr-20-154.
7. Bleijs M, van de Wetering M, Clevers H, Drost J. Xenograft and organoid
model systems in cancer research. EMBO J. 2019. https://doi.org/10.
15252/embj.2019101654.
8. Pompili L, Porru M, Caruso C, Biroccio A, Leonetti C. Patient-derived
xenografts: a relevant preclinical model for drug development. J Exp Clin
Cancer Res. 2016;35(1):189. https://doi.org/10.1186/s13046-016-0462-4.
9. Kita K, Fukuda K, Takahashi H, Tanimoto A, Nishiyama A, Arai S, Takeuchi S,
Yamashita K, Ohtsubo K, Otani S, Yanagimura N, Suzuki C, Ikeda H, Tamura
M, Matsumoto I, Yano S. Patient-derived xenograft models of non-small
cell lung cancer for evaluating targeted drug sensitivity and resistance.
Cancer Sci. 2019;110(10):3215–24. https://doi.org/10.1111/cas.14171.
10. John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, Panchal D, Hui F,
Meng F, Shepherd FA, Tsao MS. The ability to form primary tumor xeno‑
grafts is predictive of increased risk of disease recurrence in early-stage
Miura et al. Cancer Cell International
11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. (2023) 23:34
non-small cell lung cancer. Clin Cancer Res. 2011;17(1):134–41. https://
doi.org/10.1158/1078-0432.CCR-10-2224.
Chen X, Shen C, Wei Z, Zhang R, Wang Y, Jiang L, Chen K, Qiu S, Zhang
Y, Zhang T, Chen B, Xu Y, Feng Q, Huang J, Zhong Z, Li H, Che G, Xiao K.
Patient-derived non-small cell lung cancer xenograft mirrors complex
tumor heterogeneity. Cancer Biol Med. 2021;18(1):184–98. https://doi.
org/10.20892/j.issn.2095-3941.2020.0012.
Takebe T, Enomura M, Yoshizawa E, Kimura M, Koike H, Ueno Y, Matsuzaki
T, Yamazaki T, Toyohara T, Osafune K, Nakauchi H, Yoshikawa HY, Taniguchi
H. Vascularized and complex organ buds from diverse tissues via mes‑
enchymal cell-driven condensation. Cell Stem Cell. 2015;16(5):556–65.
https://doi.org/10.1016/j.stem.2015.03.004.
Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang RR,
Ueno Y, Zheng YW, Koike N, Aoyama S, Adachi Y, Taniguchi H. Vascularized
and functional human liver from an iPSC-derived organ bud transplant.
Nature. 2013. https://doi.org/10.1038/nature12271.
Ogawa H, Koyanagi-Aoi M, Otani K, Zen Y, Maniwa Y, Aoi T. Interleukin-6
blockade attenuates lung cancer tissue construction integrated by
cancer stem cells. Sci Rep. 2017;7(1):12317. https://doi.org/10.1038/
s41598-017-12017-y.
Chu PY, Koh AP, Antony J, Huang RY. Applications of the chick chorioallan‑
toic membrane as an alternative model for cancer studies. Cells Tissues
Organs. 2021. https://doi.org/10.1159/000513039.
DeBord LC, Pathak RR, Villaneuva M, Liu HC, Harrington DA, Yu W, Lewis
MT, Sikora AG. The chick chorioallantoic membrane (CAM) as a versatile
patient-derived xenograft (PDX) platform for precision medicine and
preclinical research. Am J Cancer Res. 2018;8(8):1642–60.
Huang WT, Cen WL, He RQ, Xie Y, Zhang Y, Li P, Gan TQ, Chen G, Hu XH.
Effect of miR146a5p on tumor growth in NSCLC using chick chorioal‑
lantoic membrane assay and bioinformatics investigation. Mol Med Rep.
2017;16(6):8781–92. https://doi.org/10.3892/mmr.2017.7713.
Ishida R, Koyanagi-Aoi M, Oshima N, Kakeji Y, Aoi T. The tissue-reconstruct‑
ing ability of colon cscs is enhanced by FK506 and suppressed by GSK3
inhibition. Mol Cancer Res. 2017;15(10):1455–66. https://doi.org/10.1158/
1541-7786.
Nowak-Sliwinska P, Segura T, Iruela-Arispe ML. The chicken chorioallantoic
membrane model in biology, medicine and bioengineering. Angiogen‑
esis. 2014;17(4):779–804. https://doi.org/10.1007/s10456-014-9440-7.
Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization:
alternative therapeutic targets. Angiogenesis. 2017;20(4):409–26. https://
doi.org/10.1007/s10456-017-9562-9.
Fergelot P, Bernhard JC, Soulet F, Kilarski WW, Léon C, Courtois N,
Deminière C, Herbert JM, Antczak P, Falciani F, Rioux-Leclercq N, Patard JJ,
Ferrière JM, Ravaud A, Hagedorn M, Bikfalvi A. The experimental renal cell
carcinoma model in the chick embryo. Angiogenesis. 2013;16(1):181–94.
https://doi.org/10.1007/s10456-012-9311-z.
Scalise M, Pochini L, Console L, Losso MA, Indiveri C. The human SLC1A5
(ASCT2) amino acid transporter: from function to structure and role in
cell biology. Front Cell Dev Biol. 2018;6:96. https://doi.org/10.3389/fcell.
2018.00096.
Miyaho RN, Nakagawa S, Hashimoto-Gotoh A, Nakaya Y, Shimode S,
Sakaguchi S, Yoshikawa R, Takahashi MU, Miyazawa T. Corrigendum to
“susceptibility of domestic animals to pseudotype virus bearing RD-114
virus envelope protein. Gene. 2019;690:137. https://doi.org/10.1016/j.
gene.2019.01.002.
Nitzsche B, Rong WW, Goede A, Hoffmann B, Scarpa F, Kuebler WM,
Secomb TW, Pries AR. Coalescent angiogenesis-evidence for a novel
concept of vascular network maturation. Angiogenesis. 2022;25(1):35–45.
https://doi.org/10.1007/s10456-021-09824-3.
Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treat‑
ment of solid malignancies. Clin Ther. 2006;28(11):1779–802. https://doi.
org/10.1016/j.clinthera.2006.11.015.
Hagedorn M, Zilberberg L, Wilting J, Canron X, Carrabba G, Giussani
C, Pluderi M, Bello L, Bikfalvi A. Domain swapping in a COOH-terminal
fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Cancer Res. 2002;62(23):6884–90.
D’Abadia PL, BailÃo EFLC, Lino J, Únior RS, Oliveira MG, Silva VB, Oliveira
LAR, ConceiÇÃo EC, Melo-Reis PR, Borges LL, GonÇalves PJ, Almeida LM.
Hancornia speciosa serum fraction latex stimulates the angiogenesis
and extracellular matrix remodeling processes. An Acad Bras Cienc.
2020;92(2): e20190107.
Page 13 of 13
28. DeFouw DO, Rizzo VJ, Steinfeld R, Feinberg RN. Mapping of the
microcirculation in the chick chorioallantoic membrane during normal
angiogenesis. Microvasc Res. 1989;38(2):136–47. https://doi.org/10.1016/
0026-2862(89)90022-8.
29. Ribatti D, Nico B, Vacca A, Presta M. The gelatin sponge-chorioallantoic
membrane assay. Nat Protoc. 2006;1(1):85–91. https://doi.org/10.1038/
nprot.2006.13.
30. Nowak-Sliwinska P, Ballini JP, Wagnières G, van den Bergh H. Processing
of fluorescence angiograms for the quantification of vascular effects
induced by anti-angiogenic agents in the CAM model. Microvasc Res.
2010;79(1):21–8. https://doi.org/10.1016/j.mvr.2009.10.004.
31. Gomez A, Bindesbøll C, Satheesh SV, Grimaldi G, Hutin D, MacPherson
L, Ahmed S, Tamblyn L, Cho T, Nebb HI, Moen A, Anonsen JH, Grant DM,
Matthews J. Characterization of TCDD-inducible poly-ADP-ribose poly‑
merase (TIPARP/ARTD14) catalytic activity. Biochem J. 2018;475(23):3827–
46. https://doi.org/10.1042/BCJ20180347.
32. Gualtieri M, Longhin E, Mattioli M, Mantecca P, Tinaglia V, Mangano E,
et al. Gene expression profiling of A549 cells exposed to Milan PM25.
Toxicol Lett. 2012;209(2):136–45. https://doi.org/10.1016/j.toxlet.2011.11.
015.
33. Melander MC, Jürgensen HJ, Madsen DH, Engelholm LH, Behrendt N. The
collagen receptor uPARAP/Endo180 in tissue degradation and cancer
(Review). Int J Oncol. 2015;47(4):1177–88. https://doi.org/10.3892/ijo.
2015.3120.
34. Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A, Bik‑
falvi A. Accessing key steps of human tumor progression in vivo by using
an avian embryo model. Proc Natl Acad Sci USA. 2005;102(5):1643–8.
https://doi.org/10.1073/pnas.0408622102.
35. Pawlikowska P, Tayoun T, Oulhen M, Faugeroux V, Rouffiac V, Aberlenc
A, Pommier AL, Honore A, Marty V, Bawa O, Lacroix L, Scoazec JY,
Chauchereau A, Laplace-Builhe C, Farace F. Exploitation of the chick
embryo chorioallantoic membrane (CAM) as a platform for anti-meta‑
static drug testing. Sci Rep. 2020;10(1):16876. https://doi.org/10.1038/
s41598-020-73632-w.
36. Gozgit JM, Vasbinder MM, Abo RP, Kunii K, Kuplast-Barr KG, Gui B, Lu
AZ, Molina JR, Minissale E, Swinger KK, Wigle TJ, Blackwell DJ, Majer CR,
Ren Y, Niepel M, Varsamis ZA, Nayak SP, Bamberg E, Mo JR, Church WD,
Mady ASA, Song J, Utley L, Rao PE, Mitchison TJ, Kuntz KW, Richon VM,
Keilhack H. PARP7 negatively regulates the type I interferon response in
cancer cells and its inhibition triggers antitumor immunity. Cancer Cell.
2021;39(9):1214-1226.e10. https://doi.org/10.1016/j.ccell.2021.06.018.
37. Palavalli Parsons LH, Challa S, Gibson BA, Nandu T, Stokes MS, Huang
D, Lea JS, Kraus WL. Identification of PARP-7 substrates reveals a role
for MARylation in microtubule control in ovarian cancer cells. eLife.
2021;10:e60481. https://doi.org/10.7554/eLife.60481.
38. Zhang L, Cao J, Dong L, Lin H. TiPARP forms nuclear condensates to
degrade HIF-1α and suppress tumorigenesis. Proc Natl Acad Sci U S A.
2020;117(24):13447–56. https://doi.org/10.1073/pnas.1921815117.
39. Abdel-Hamid NM, Abass SA. Matrix metalloproteinase contribu‑
tion in management of cancer proliferation, metastasis and drug
targeting. Mol Biol Rep. 2021;48(9):6525–38. https://doi.org/10.1007/
s11033-021-06635-z.
40. Nagase H, Visse R, Murphy G. Structure and function of matrix metal‑
loproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562–73. https://doi.
org/10.1016/j.cardiores.2005.12.002.
41. Rijo MP, Diani-Moore S, Yang C, Zhou P, Rifkind AB. Roles of the ubiquitin
ligase CUL4B and ADP-ribosyltransferase TiPARP in TCDD-induced nuclear
export and proteasomal degradation of the transcription factor AHR. J
Biol Chem. 2021;297(2):100886. https://doi.org/10.1016/j.jbc.2021.100886.
42. Ribatti D. The chick embryo chorioallantoic membrane (CAM) assay.
Reprod Toxicol. 2017;70:97–101. https://doi.org/10.1016/j.reprotox.2016.
11.004.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
...
論文の公開元へ
